Evidence map›Paper›PMID 37958342›Full record

ArticleCancers2023

Heparan-6-

Pritha Mukherjee, Xin Zhou, Julius Benicky, Aswini Panigrahi, Reem Aljuhani, Jian Liu, Laurie Ailles, Vitor H Pomin, Zhangjie Wang, Radoslav Goldman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Pritha MukherjeeDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0001-6573-4580
Xin ZhouDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Julius BenickyDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Aswini PanigrahiDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.
Reem AljuhaniClinical and Translational Glycoscience Research Center, Georgetown University, Washington, DC 20057, USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Laurie AillesDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, Oxford, MS 38677, USA.ORCID 0000-0002-5015-8880
Zhangjie WangGlycan Therapeutics, LLC, 617 Hutton Street, Raleigh, NC 27606, USA.
Radoslav GoldmanDepartment of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA.ORCID 0000-0003-1304-0522
Georgetown University · USUniversity Health Network · CAUniversity of Mississippi · USUniversity of North Carolina at Chapel Hill · US

Funding

O-glycoproteins in the progression of liver diseaseR01CA238455 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2019 to 2023
$2.6M
LC-MS Analysis of Site Specific Protein GlycoformsU01CA230692 · NCI · GEORGETOWN UNIVERSITY · PI EDWARDS, NATHAN J, GOLDMAN, RADOSLAV · 2018 to 2020
$1.3M
Orbitrap Fusion Lumos ETDS10OD023557 · OD · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2017 to 2017
$1.1M
Development of a sensitive method to measure heparan sulfate 6-O-endosulfataseR43GM149008 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI SU, GUOWEI · 2023 to 2023
$350k
NCI NIH HHS R01 CA238455NCI NIH HHS U01 CA230692NIGMS NIH HHS R43 GM149008NIH HHS S10 OD023557
6 · The paper itself

Abstract

Local invasiveness of head and neck squamous cell carcinoma (HNSCC) is a complex phenomenon supported by interaction of the cancer cells with the tumor microenvironment (TME). We and others have shown that cancer-associated fibroblasts (CAFs) are a component of the TME that can promote local invasion in HNSCC and other cancers. Here we report that the secretory enzyme heparan-6-

Indexed as

cancer-associated fibroblastcancer invasionhead and neck squamous cell carcinomaheparan-6-O-endosulfataseSulf-2 CRISPRCas9 knockoutSulf-2 inhibitor

Identifiers

PMID37958342
PMCPMC10650326
OpenAlexW4387975888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.